Medicinal Cannabis Research and Development
Cannasouth is a Science-Led company with ongoing commercially focused research programmes targeted at developing next-generation medicinal cannabis products and valuable IP.
Medicinal cannabis research is at the heart of what we do and is a core value in our companies’ vision. We have extensive research programmes making Cannasouth the leader in the New Zealand medicinal cannabis industry.
Cannasouth has a commercially focused R&D facility based in New Zealand that is involved in multiple areas of research, from chemistry (identification, extraction, and isolation of bioactive compounds) to biological sciences (preclinical investigations) and new product development (drug delivery technology).
Our R&D Team includes highly qualified and experienced scientists with GMP and pharmaceutical R&D experience. Our research laboratories are equipped with advanced technology for targeting and isolating cannabinoids to feed into our formulation and clinical development programmes.
Cannasouth has been successful in achieving significant Government funding via Callaghan Innovation for many of our research initiatives. This research, combined with our preclinical studies, allows Cannasouth to search for genuine, unique IP opportunities, develop clinical trial strategies, and develop innovative new products and formulations for local and export markets.
Cannasouth R&D team is currently working with Government funding via Callaghan Innovation and in collaboration with academic centers of excellence in New Zealand in the following areas:
|Fellowship Grant||PhD: the Extraction of bioactives using Supercritical Fluid CO2 extraction, short path molecular distillation and purification research||In final year of three-year programme|
|Fellowship Grant||MSc: Tissue Culture to identify and optimize cultivation processes||Submitted February 2021|
|Fellowship Grant||MSc: To create a cannabinoid and receptor docking library using computational chemistry||Commenced March 2021|
|Project Grant||PhD: Drug Discovery, Neuropathic pain research In-house Research: Improved Drug Delivery technologies||Half-way into a three-year programme|
|Career Grant||Placement of a Fellowship Grant MSc student into full-time R&D role||February to August 2021|
Cannabinoid Chemistry (Ph.D.).
This project covers the science of extraction, fractionation, purification, and degradation dynamics of specific phytocannabinoid compounds and chemicals found naturally in cannabis.
It involves the use of leading-edge purification technology able to separate all the major and minor cannabinoids to upwards of 99%+ purity.
Tissue Culture & Medicinal Cannabis (M.Sc.).
In-vitro tissue culture (micropropagation) of cannabis offers many potential advantages over the more widely used cutting-based method for producing clonal cannabis plants.
Tissue culture enables superior genetic stability, cultivar storage enhancement, and aseptic culture free of pests and disease.
Cannabinoids & Neuropathic Pain (Ph.D.).
This research is focused on neuropathic pain and cannabinoid compound efficacy validation.
The aim is to assess the efficacy of discrete bioactive compounds extracted from cannabis in preclinical models of neuropathic pain to define optimal formulations, dosage, and relevant clinical indications.
Computational Chemistry (M.Sc.)
This project aims to gain an understanding of bioactive compounds from cannabis and their interaction with biological receptors.
This will help identify new and existing molecules’ biological activity and pharmacology and direct future clinical research.
This internal project aims to identify advanced drug delivery technologies to enhance the performance of medicinal cannabis products. The focus is on improving bioavailability, safety, and patient compliance with novel formulations and alternative routes of delivery.
Masters – CBD Purification
This Masters study involved raw cannabis compounds purified via analytical and preparative HPLC systems.
Fractions were screened by 1H NMR spectroscopy and analysed by GC mass spectrometry resulting in the production of high purity 99%+ compounds of CBD, CBDA, THC & THCA produced from Cannasouth’s New Zealand growing trials.
To continuously develop new medicinal cannabis therapeutics to improve patient outcomes.
Our laboratories are equipped with state-of-the-art technology to efficiently extract and refine the bioactive compounds, including cannabinoids, flavonoids, and terpenes. Finally, we formulate and process these compounds into a wide range of innovative therapeutic cannabinoid-based solutions for clinicians, doctors, and patients.
Cannasouth operates two cultivation facilities. Near our headquarters in Hamilton have an indoor, fully climate-controlled research, quarantine, and support facility.
We have also constructed a commercial production Controlled Environment Agriculture (CEA) sealed greenhouse.
This approach takes all the precise climate and biosecurity control features of an indoor environment but introduces sunlight as the primary light source.
The extraction and purification of bioactive compounds from the plant material are critical to the quality of the end-products.
Cannasouth research laboratories are equipped with state-of-the-art extraction technology, and this is now being replicated at the commercial scale at our GMP manufacturing facility in New Zealand.
The technology is designed to protect valuable chemical compounds during the process.
Cannasouth will be formulating its product ranges to the highest standards to create innovative cannabinoid medicines to support patient health outcomes.
Offering therapeutic solutions and formulations tailored to specific needs and medical conditions for a broad range of health problems and illness conditions requiring treatment.